Literature DB >> 17889349

Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation.

Elizabeth O Hexner1, Gwenn-Aël H Danet-Desnoyers, Yi Zhang, Dale M Frank, James L Riley, Bruce L Levine, David L Porter, Carl H June, Stephen G Emerson.   

Abstract

Clinical experience and animal models have shown that donor T cell depletion (TCD) adversely affects engraftment of hematopoietic stem cells (HSCs). Although it is known that donor T cells are acting to overcome residual host immune barriers, they may also exert effects independent of host resistance via direct or indirect interactions with donor stem cells, their microenvironment, or key differentiation events. To more precisely define the effect of T cells on engraftment, we have performed human umbilical cord blood (UCB) transplantation into immunodeficient mice under limiting dilution conditions. UCB mononuclear cells (MNC) or TCD UCB were transplanted into NOD/LtSz-scid/scid B2m(null) (NOD/SCID-beta(2)m(-/-)) mice. Cohorts of mice received UCB MNC or TCD UCB at 5 dose levels between 5 x 10(4) and 5 x 10(6) cells. At dose levels at or above 10(5) cells, engraftment was higher in the MNC recipients (n = 32) than the TCD recipients (n = 31) in a dose-dependent manner. Despite this difference, limiting dilution analysis to determine functional stem cell frequency revealed that SCID repopulating cells in TCD UCB was not significantly less than in CB MNCs, suggesting that T cells may facilitate engraftment at stages beyond the stem cell. Add-back of CD3/CD28 costimulated T cells restored and appeared to enhance engraftment, both in NOD/SCID-beta(2)m(-/-) as well as NOD/LtSz-scid IL2Rgamma(null) (NOG) recipients. These results, in a model where there are minimal host immune barriers to overcome, suggest T cells possess additional graft-facilitating properties. CD3/CD28 costimulation of UCB T cells represents a potential strategy for enhancing the engraftment of UCB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17889349     DOI: 10.1016/j.bbmt.2007.06.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation.

Authors:  Craig C Davis; Luciana C Marti; Gregory D Sempowski; Durairaj A Jeyaraj; Paul Szabolcs
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Pharmacologic eigenvalues: beating the rap on bone marrow failure.

Authors:  Stephen G Emerson; Russell W Garrett
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

3.  HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection.

Authors:  Cladd E Stevens; Carmelita Carrier; Carol Carpenter; Dorothy Sung; Andromachi Scaradavou
Journal:  Blood       Date:  2011-07-12       Impact factor: 22.113

Review 4.  Adoptive immunotherapy: good habits instilled at youth have long-term benefits.

Authors:  Chrystal M Paulos; Megan M Suhoski; Gabriela Plesa; Tianying Jiang; Samik Basu; Tatiana N Golovina; Shuguang Jiang; Nicole A Aqui; Daniel J Powell; Bruce L Levine; Richard G Carroll; James L Riley; Carl H June
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

5.  Umbilical cord blood processing using Prepacyte-CB increases haematopoietic progenitor cell availability over conventional Hetastarch separation.

Authors:  C Basford; N Forraz; S Habibollah; K Hanger; C P McGuckin
Journal:  Cell Prolif       Date:  2009-09-15       Impact factor: 6.831

6.  Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study.

Authors:  L G Lum; A Thakur; C Pray; N Kouttab; M Abedi; A Deol; W M Colaiace; R Rathore
Journal:  Bone Marrow Transplant       Date:  2013-09-23       Impact factor: 5.483

7.  Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants.

Authors:  Archana Thakur; Carly Sorenson; Oxana Norkina; Dana Schalk; Voravit Ratanatharathorn; Lawrence G Lum
Journal:  Transfusion       Date:  2011-07-11       Impact factor: 3.157

8.  An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment.

Authors:  Lamis K Eldjerou; Sonali Chaudhury; Ada Baisre-de Leon; Mai He; Maria E Arcila; Glenn Heller; Richard J O'Reilly; Juliet N Barker; Malcolm A Moore
Journal:  Blood       Date:  2010-06-29       Impact factor: 22.113

9.  OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues.

Authors:  Mark Wunderlich; Ryan A Brooks; Rushi Panchal; Garrett W Rhyasen; Gwenn Danet-Desnoyers; James C Mulloy
Journal:  Blood       Date:  2014-04-28       Impact factor: 22.113

10.  CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.

Authors:  Lawrence G Lum; Archana Thakur; Qin Liu; Abhinav Deol; Zaid Al-Kadhimi; Lois Ayash; Muneer H Abidi; Cassara Pray; Elyse N Tomaszewski; Patricia A Steele; Dana L Schalk; Hiroshi Yano; Alice Mitchell; Melissa Dufresne; Joseph P Uberti; Voravit Ratanatharathorn
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-22       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.